1. Volume 31, Issue 4, Pages 563-575.e5 (April 2017)
Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression 
Ashleigh R. Poh, Christopher G. Love, Frederick Masson, Adele Preaudet, Cary Tsui, Lachlan Whitehead, Simon Monard, Yelena Khakham, Lotta Burstroem, Guillaume Lessene, Oliver Sieber, Clifford Lowell, Tracy L. Putoczki, Robert J.J. O'Donoghue, Matthias Ernst 
Cancer Cell 
Volume 31, Issue 4, Pages e5 (April 2017)
DOI: /j.ccell
Copyright © 2017 Elsevier Inc. Terms and Conditions

2. Cancer Cell 2017 31, 563-575.e5DOI: (10.1016/j.ccell.2017.03.006)
Copyright © 2017 Elsevier Inc. Terms and Conditions

3. Figure 1
HCK Expression Correlates with Poor Survival and Increased Expression of Genes Related to Alternative Activation of Macrophages
(A) Western blot analysis of the phosphorylated protein isoforms of p59/61HCK (arrows) in paired biopsies of normal human colon (N) and corresponding CRC adenocarcinoma (T). To assess for protein abundance, the membrane was probed for ACTIN.
(B) Correlation between HCK mRNA expression (fold-change relative to ACTIN) and abundance of phosphorylated p-HCK (fold-change relative to total HCK protein) expressed as fold-change in paired biopsies of normal human colon and CRC tumors analyzed in (A). Numbers refer to individual patient samples. Pearson correlation coefficient and p value are indicated.
(C) Immunofluorescence staining of HCK, CD45, and EpCAM in a representative sample from the matched human CRC tumors in (A). Nuclei are visualized by DAPI staining. Scale bar, 100 μm.
(D) Overall survival of human sporadic CRC patients from two independent datasets (GEO: GSE16125 and GSE17537) and assigned at the median of HCK expression into HCKLow and HCKHigh cohorts.
(E) Analysis of genes differentially expressed between HCKLow and HCKHigh human sporadic colorectal tumors using the TCGA dataset (see Supplemental Information). Of the top 100 overexpressed genes in the HCKHigh cohort, those associated with CAM or AAM polarization are shown (see text).
See also Figure S1 and Table S1.
Cancer Cell  , e5DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

4. Figure 2
Constitutive Hck Activation Enhances Sporadic Colorectal Tumor Development in Mice
(A) Photomicrograph of representative colons from WT and HckCA mice collected 16 weeks after the last of 6 consecutive challenges with AOM to induce sporadic CRC. Arrows indicate tumors. Scale bar, 1 cm.
(B) Enumeration of total tumor burden and of tumors following classification according to their size. Each symbol represents data from an individual mouse treated as described for (A). ∗p <
(C) Western blot analysis of tumor cell lysates from individual mice treated as described for (A). The Stat3 and Erk1/2 isoforms are indicated by arrows. Membranes were probed sequentially using actin and Erk1/2 as loading controls.
(D) Il6 and Il11 mRNA expression in tumors of WT and HckCA mice, n = 3 mice per cohort. ∗p < 0.05.
All data are represented as mean ± SEM, with p values from unpaired Student's t test.
See also Figure S2.
Cancer Cell  , e5DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

5. Figure 3 HckCA in Hematopoietic Cells Promotes Sporadic Tumorigenesis
(A) Hck mRNA expression of FACS-purified CD45+CD11b+F4/80+ tumor-associated macrophages (TAMs) and of EpCAM+ tumor epithelial cells (TECs) prepared from tumors of WT and HckCA mice, n = 3 mice per cohort. n.d, not detected.
(B) Photomicrographs of representative colons of reciprocal WT and HckCA bone marrow chimeras collected 16 weeks after the last of 6 consecutive AOM challenges. Arrows indicate tumors. Scale bar, 1 cm.
(C) Enumeration of total tumor burden and of tumors following classification according to their size. Each symbol represents data from an individual mouse as described for (B). ∗p < 0.01, ∗∗p <
(D) Western blot analysis of tumor cell lysates from individual mice as described for (B). The Stat3 and Erk1/2 isoforms are indicated by arrows. Actin was used as a loading control for the blot showing the phosphorylated isoforms; Erk1/2 was used as the loading control for blots showing the un-phosphorylated isoforms.
(E) Enumeration of total tumor burden and of tumors following classification according to their size. Each symbol represents data from an individual mouse collected 16 weeks after the last of 6 consecutive challenges with AOM to induce sporadic CRC. ∗∗p <
All data are represented as mean ± SEM, with p values from unpaired Student's t test, See also Figure S3.
Cancer Cell  , e5DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

6. Figure 4
Enhanced Hck Activation in Sporadic Colon Tumors Correlates with an Alternatively Activated Macrophage Gene Signature
(A) qPCR analysis for the expression of genes associated with CAM (Il1β, Tnfα, Nos2, and CD86) and AAM activation (Il4, Il10, Il13, Arg1, and Ym1) in tumors and adjacent unaffected colon sections of WT and HckCA mice, either treatment-naive (control) or 16 weeks after the last of 6 consecutive challenges with AOM to induce sporadic CRC, n ≥ 4 mice per cohort.
(B) Quantification of CD206+ macrophages (CD45+CD11b+F4/80+) by flow cytometry from sporadic colon tumors of WT and HckCA mice 16 weeks after the last of 6 consecutive AOM challenges. Each symbol represents data from an individual mouse.
(C) qPCR analysis on FACS-purified CD45+CD11b+F4/80+ tumor-associated macrophages for CAM- (Cd86, Nos2, Il1β, and Tnfα) and AAM-associated genes (Il4, Il10, Il13, Arg1, Ym1, and Tie2), n = 3 mice per cohort.
(D) qPCR analysis on FACS-purified CD45+CD11b+F4/80+ tumor-associated macrophages collected from reciprocal bone marrow chimeras of the indicated genotypes, n = 4 mice per cohort.
All data are represented as mean ± SEM, with p values from unpaired Student's t test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p <
See also Figure S4.
Cancer Cell  , e5DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

7. Figure 5
Enhanced Hck Activation Drives Sporadic Colon Tumorigenesis and AAM Differentiation through Non-canonical Pathways
(A and C) Enumeration of total tumor burden and of tumors following classification according to their size. Each symbol represents data from an individual mouse collected 16 weeks after the last of 6 consecutive challenges with AOM to induce sporadic CRC. ∗p < 0.01, ∗∗p <
(B and D) qPCR expression analysis of CAM- (Il1β, Tnfα, and Nos2) and AAM-associated genes (Il4, Il10, Arg1, and Ym1) in tumors of mice of the indicated genotype, n ≥ 4 mice per cohort. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p <
All data are represented as mean ± SEM, with p values from unpaired Student's t test.
See also Figure S5.
Cancer Cell  , e5DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

8. Figure 6
Genetic or Pharmacologic Inhibition of Hck Signaling Restrains Growth of MC38 CRC Allografts
(A) Weight of individual subcutaneous tumors from HckCA;Cfms+/+ or HckCA;Cfms+/– hosts following inoculation of syngeneic MC38 cells. Each symbol represents a tumor from an individual mouse. Some tumors required earlier collection due to excessive ulceration.
(B) Weight of allograft tumors excised from WT or HckKO mice. Where indicated, mice were treated for 1 week with RK20449 (30 mg/kg) when allografts became palpable. Each symbol represents data from an individual mouse.
(C) Weight of allograft tumors excised from WT mice after systemic treatment with vehicle (12% Captisol), inactive stereoisomer (30 mg/kg), or RK20449 (30 mg/kg) for 1 week. Treatment commenced when allografts became palpable. Each symbol represents data from an individual mouse.
(D) Flow cytometric quantification of CD206-expressing CD45+CD11b+F4/80+ macrophages isolated from allografts grown in mice treated as in (B) and (C). Each symbol represents data from an individual mouse.
(E) qPCR analysis on whole-allograft tumors of the indicated treatment cohort from (C), n = 3 mice per cohort.
(F) qPCR analysis on whole-allograft tumors grown in the mice of the indicated genotypes and treated as in (B), n = 3 mice per cohort.
All data are represented as mean ± SEM, with p values from unpaired Student's t test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p <
See also Figure S6.
Cancer Cell  , e5DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

9. Figure 7
Pharmacologic Inhibition of Hck Signaling Impairs Growth of Human CRC Xenografts
(A) Weight of xenograft tumors excised from Rag1KO mice treated with RK20449 (30 mg/kg), its biologically inactive stereoisomer (30 mg/kg), or vehicle. Mice were treated for 10 days once subcutaneous xenografts became palpable. Each symbol represents data from an individual mouse.
(B) Western blot analysis for the phosphorylated forms of selected SFKs in HCT116, DLD1 and SW480 xenografts excised from mice of the indicated treatment cohort. Each lane represents an individual mouse treated as described in (A). The mouse p56/59Hck and p60Src isoforms are indicated by arrows. Actin was used as a loading control.
(C) Flow cytometric quantification of CD206-expressing CD45+CD11b+F4/80+ macrophages isolated from HCT116, DLD1, and SW480 CRC cell xenografts grown in mice treated as in (A). Each symbol represents data from an individual mouse.
All data are represented as mean ± SEM, with p values from unpaired Student's t test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p <
See also Figure S7.
Cancer Cell  , e5DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

10. Figure 8
Hck Mediates Induction of the AAM Endotype Independently of Stat3
(A) Representative H&E and co-immunofluorescence stains for Hck and p-Stat3 on WT and HckCA sporadic CRC and CAC tumors. Nuclei are visualized by DAPI staining. Scale bar, 100 μm.
(B) Arg1 and Nos2 mRNA expression in naive (untreated) and IL-6/IL-11-stimulated WT and HckCA BMDMs, n = 3 mice per cohort.
(C) qPCR expression analysis for Stat3-target genes on FACS-purified CD45+CD11b+F4/80+ macrophages collected from sporadic CRC and CAC tumors of WT and HckCA mice, n = 4 mice per cohort.
(D) Western Blot analysis for phosphorylated Stat3 in naive WT, HckCA, and HckKO BMDMs. The Stat3 isoforms are indicated by arrows. Actin was used as a loading control.
(E) Arg1 and Ym1 mRNA expression in naive BMDMs of the indicated genotypes from (D), n = 3 mice per cohort.
(F) Arg1 and Ym1 mRNA expression in Stat3+/− and HckCA BMDMs either treated with IL-4/IL-13 (20 ng/mL) or Stattic (10 μM), n = 3 mice per cohort.
Data are represented as mean ± SEM, with p values from unpaired Student's t test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p <
See also Figure S8.
Cancer Cell  , e5DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions